Cargando…
Apolipoprotein A1 as a novel anti-implantation biomarker in polycystic ovary syndrome: A case-control study
BACKGROUND: Women with polycystic ovary syndrome have lower pregnancy rates, possibly due to the decreased uterine receptivity. Successful implantation depends on protein networks that are essential for cross-talk between the embryo and endometrium. Apolipoprotein A1 has been proposed as a putative...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755089/ https://www.ncbi.nlm.nih.gov/pubmed/26941806 http://dx.doi.org/10.4103/1735-1995.172813 |
_version_ | 1782416142530248704 |
---|---|
author | Amjadi, Fatemehsadat Aflatoonian, Reza Javanmard, Shaghayegh Haghjoo Saifi, Bita Ashrafi, Mahnaz Mehdizadeh, Mehdi |
author_facet | Amjadi, Fatemehsadat Aflatoonian, Reza Javanmard, Shaghayegh Haghjoo Saifi, Bita Ashrafi, Mahnaz Mehdizadeh, Mehdi |
author_sort | Amjadi, Fatemehsadat |
collection | PubMed |
description | BACKGROUND: Women with polycystic ovary syndrome have lower pregnancy rates, possibly due to the decreased uterine receptivity. Successful implantation depends on protein networks that are essential for cross-talk between the embryo and endometrium. Apolipoprotein A1 has been proposed as a putative anti-implantation factor. In this study, we evaluated apolipoprotein A1 expression in human endometrial tissues. MATERIALS AND METHODS: Endometrial apolipoprotein A1 messenger RNA (mRNA) and protein expression were investigated using quantitative real-time polymerase chain reaction (PCR) and Western blot. The distribution of apolipoprotein A1 was also detected by immunostaining. Samples were obtained from 10 patients with polycystic ovary syndrome and 15 healthy fertile women in the proliferative (on day 2 or day 3 before ovulation, n = 7) and secretory (on days 3-5 after ovulation, n = 8) phases. RESULTS: Endometrial apolipoprotein A1 expression was upregulated in patients with polycystic ovary syndrome compared to normal subjects. However, apolipoprotein A1 expression in the proliferative phase was significantly higher than in the luteal phase (P value < 0.05). CONCLUSION: It seems that differentially expressed apolipoprotein A1 negatively affects endometrial receptivity in patients with polycystic ovary syndrome. The results showed that apolipoprotein A1 level significantly changes in the human endometrium during the menstrual cycle with minimum expression in the secretory phase, coincident with the receptive phase (window of implantation). Further studies are required to clarify the clinical application of this protein. |
format | Online Article Text |
id | pubmed-4755089 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-47550892016-03-03 Apolipoprotein A1 as a novel anti-implantation biomarker in polycystic ovary syndrome: A case-control study Amjadi, Fatemehsadat Aflatoonian, Reza Javanmard, Shaghayegh Haghjoo Saifi, Bita Ashrafi, Mahnaz Mehdizadeh, Mehdi J Res Med Sci Original Article BACKGROUND: Women with polycystic ovary syndrome have lower pregnancy rates, possibly due to the decreased uterine receptivity. Successful implantation depends on protein networks that are essential for cross-talk between the embryo and endometrium. Apolipoprotein A1 has been proposed as a putative anti-implantation factor. In this study, we evaluated apolipoprotein A1 expression in human endometrial tissues. MATERIALS AND METHODS: Endometrial apolipoprotein A1 messenger RNA (mRNA) and protein expression were investigated using quantitative real-time polymerase chain reaction (PCR) and Western blot. The distribution of apolipoprotein A1 was also detected by immunostaining. Samples were obtained from 10 patients with polycystic ovary syndrome and 15 healthy fertile women in the proliferative (on day 2 or day 3 before ovulation, n = 7) and secretory (on days 3-5 after ovulation, n = 8) phases. RESULTS: Endometrial apolipoprotein A1 expression was upregulated in patients with polycystic ovary syndrome compared to normal subjects. However, apolipoprotein A1 expression in the proliferative phase was significantly higher than in the luteal phase (P value < 0.05). CONCLUSION: It seems that differentially expressed apolipoprotein A1 negatively affects endometrial receptivity in patients with polycystic ovary syndrome. The results showed that apolipoprotein A1 level significantly changes in the human endometrium during the menstrual cycle with minimum expression in the secretory phase, coincident with the receptive phase (window of implantation). Further studies are required to clarify the clinical application of this protein. Medknow Publications & Media Pvt Ltd 2015-11 /pmc/articles/PMC4755089/ /pubmed/26941806 http://dx.doi.org/10.4103/1735-1995.172813 Text en Copyright: © Journal of Research in Medical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Amjadi, Fatemehsadat Aflatoonian, Reza Javanmard, Shaghayegh Haghjoo Saifi, Bita Ashrafi, Mahnaz Mehdizadeh, Mehdi Apolipoprotein A1 as a novel anti-implantation biomarker in polycystic ovary syndrome: A case-control study |
title | Apolipoprotein A1 as a novel anti-implantation biomarker in polycystic ovary syndrome: A case-control study |
title_full | Apolipoprotein A1 as a novel anti-implantation biomarker in polycystic ovary syndrome: A case-control study |
title_fullStr | Apolipoprotein A1 as a novel anti-implantation biomarker in polycystic ovary syndrome: A case-control study |
title_full_unstemmed | Apolipoprotein A1 as a novel anti-implantation biomarker in polycystic ovary syndrome: A case-control study |
title_short | Apolipoprotein A1 as a novel anti-implantation biomarker in polycystic ovary syndrome: A case-control study |
title_sort | apolipoprotein a1 as a novel anti-implantation biomarker in polycystic ovary syndrome: a case-control study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755089/ https://www.ncbi.nlm.nih.gov/pubmed/26941806 http://dx.doi.org/10.4103/1735-1995.172813 |
work_keys_str_mv | AT amjadifatemehsadat apolipoproteina1asanovelantiimplantationbiomarkerinpolycysticovarysyndromeacasecontrolstudy AT aflatoonianreza apolipoproteina1asanovelantiimplantationbiomarkerinpolycysticovarysyndromeacasecontrolstudy AT javanmardshaghayeghhaghjoo apolipoproteina1asanovelantiimplantationbiomarkerinpolycysticovarysyndromeacasecontrolstudy AT saifibita apolipoproteina1asanovelantiimplantationbiomarkerinpolycysticovarysyndromeacasecontrolstudy AT ashrafimahnaz apolipoproteina1asanovelantiimplantationbiomarkerinpolycysticovarysyndromeacasecontrolstudy AT mehdizadehmehdi apolipoproteina1asanovelantiimplantationbiomarkerinpolycysticovarysyndromeacasecontrolstudy |